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Background: Sepsis causes high mortality, and the mortality due to secondary infections is even higher. No studies
to date have investigated the time from the primary infection to death due to a secondary infection; similarly, the
factors that are significantly different in sepsis survivors relative to non-survivors or in severe sepsis patients who
suffered a late death relative to those who recover have not been explored. We hypothesized that patients who
survive sepsis have a weaker pro-inflammatory response than those who do not and that the mid-term survivors
(which acquire secondary infections) would have a pronounced anti-inflammatory response (making them
susceptible to infection); this hypothesis was verified in this study.
Methods: We examined 24 patients with severe sepsis; the patients were subdivided by outcome into early death
(n = 5), mid-term survival (survival through severe sepsis but death within six months or continued hospitalization
for six months, n = 6), and long-term survival (recovery and survival for more than six months, n = 13) groups. The
levels of CD3+, CD4+, CD8+, and CD19+ lymphocytes were analyzed by flow cytometry, and the plasma levels of
carbonic anhydrase IX (CA IX), MCP-1, IL-6, IL-7, IL-8, and IL-10 were measured by ELISA on days 0, 1, 2, and 3. A
statistical comparison of the variables in the groups was conducted using a mixed model.
Results: The plasma levels of MCP-1, IL-6, and IL-8 in early death and survivors were significantly different, and all
had p values <0.01. The plasma levels of MCP-1, IL-6, and IL-8 were also significantly different in mid-term survivors
and long-term survivors, with p values of <0.01, 0.04, and <0.01, respectively.
Conclusions: Our data support the hypothesis that survivors have a weaker pro-inflammatory response than
non-survivors, but the mid-term survivors did not have a more pronounced anti-inflammatory response. The levels
of pro-inflammatory cytokines in the mid-term and long-term survivors were significantly different.
Keywords: MCP-1, IL-6, IL-8, IL-10, Severe sepsisBackground
Sepsis is one of main causes of death in intensive care
units (ICUs), and estimates of its prevalence range from
25% to 70% [1-5]. Sepsis often exhibits two stages con-
comitantly; systemic inflammatory response syndrome
(SIRS) releases inflammatory cytokines, and the com-
pensatory anti-inflammatory system (CARS) raises the
concentration of anti-inflammatory mediators [6,7]. This
overwhelming inflammatory response leads to early mor-
tality and tilts the precise balance of inflammation and* Correspondence: yschen1234@gmail.com
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unless otherwise stated.anti-inflammation towards recovery, and excessive anti-
inflammation often leads to secondary infections [6,8]. The
latter is known as immunoparalysis [9]. Cytokine produc-
tion precedes the expansion of CD14+CD16+ monocytes
[10]. The levels of IL-8, IL-6, and monocyte chemoattract-
ant protein-1 (MCP-1) are associated with early 48-hr and
28-day mortality in sepsis patients [11]. The duration of
immunoparalysis is not known; therefore, sepsis manage-
ment strategies do not differ for patients with the late death
or recovery outcomes because prognostic markers for the
early stages are not available. However, if these outcomes
could be predicted at an early stage, patient management
could be tailored to reduce late mortality.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pro-inflammatory response than non-survivors, while mid-
term survivors (which acquire secondary infections) would
have a more pronounced anti-inflammatory response (mak-
ing them susceptible to infection). Therefore, the plasma
levels of cytokines and lymphocyte subpopulations from
cases of early death, mid-term survivors, and long-term
survivors were measured in the early phases of severe sepsis
to verify this hypothesis.
Methods
Study population
This study was approved by the Research Review Com-
mittee of National Taiwan University Hospital (NTUH).
The enrolled severe sepsis patients were admitted to our
institution between December 10, 2010 and December
10, 2011 and had a highly probable or proven infection
and at least three of the following systemic inflamma-
tory response syndrome (SIRS) criteria: body tempe-
rature >38°C or <36°C; heart rate >90/min; breathing
frequency ≥20/min, PaCO2 < 32 mmHg, or ventilator use;
leukocyte count >12000/mm3 or <4000/mm3 or >10%
band forms; acute altered mental status; hyperglycemia
without a history of diabetes; or blood glucose > 120 mg/
dL. Other inclusion criteria were age ≥18 years, admission
to the ICU, and at least one organ failure due to sepsis
or septic shock. Septic shock was defined as sepsis with
hypotension refractory to fluid challenge. Pregnant
women, patients who had refused resuscitation, those with
known or suspected human immunodeficiency virus in-
fection, and those with known or suspected underlying
immune deficiency were excluded. The zero time point
was designated as being within 12 hours after the first
organ failure due to sepsis. Blood was collected at the zero
time point (day 0) and on days 1, 2, and 3.
Flow cytometric analysis
Blood was collected into a Vacutainer tube containing
EDTA. One hundred microliters of blood was stained
with CD3 PerCP/CD19 APC/CD4 FITC/CD 8PE (Becton
Dickinson, San Jose, California, USA) at room temperature
for 25 minutes in the dark, lysed with BD lysing solution,
washed two times with phosphate buffer saline (PBS) con-
taining 1% heat-inactivated fetal bovine serum, and fixed
with PBS containing 0.25% paraformaldehyde. For each
test, 20,000 leukocytes were collected and analyzed using a
BD FACSCalibur flow cytometer with CellQuest software
version 3.2 (Becton Dickinson, San Jose, California, USA).
Cytokine, chemokine, and carbonic anhydrase (CA)
IX analysis
Blood was collected in a sodium heparin vacutainer tube.
Plasma was collected, aliquot, and stored at −80°C until
analysis. The plasma concentrations of MCP-1, IL-6, IL-7,IL-8, and IL-10 were separately analyzed by commercial
ELISA kits according to the corresponding manufac-
turers’ instructions. The MCP-1 kit was obtained from
eBioscience (San Diego, California, USA), the IL-7 kit
was obtained from BioLegend (San Diego, California,
USA), and the other cytokine kits were obtained from
Becton Dickinson. Carbonic anhydrase (CA) IX is con-
sidered to be a marker of hypoxia [12] and was there-
fore included in the study. The CA IX kit was obtained
from Oncogene Science (Cambridge, Massachusetts,
USA).
Statistical Analysis
The patients were divided into the death or survival
groups according to outcome. The patients in the sur-
vival group were further divided into a mid-term sur-
vival group (MTSG, characterized by survival through
severe sepsis but death within six months or continued
hospitalization for six months) and long-term survival
group (LTSG, characterized by recovery from sepsis with
survival for more than six months). The groups were
evaluated at 4 different time points (Day 0, 1, 2, 3) for
ten biomarkers (CA IX, MCP-1, IL-6, IL-7, IL-8, and
IL-10, as well as the percentages of CD3+, CD4+, CD8+,
and CD19+ lymphocytes). The biomarker levels were
LOG10 transformed in all analyses.
The overall comparisons of the groups (the survival
group versus the death group and LTSG versus MTSG)
and time points for each biomarker were carried out using
a mixed model. An appropriate covariance structure
specification for each biomarker was chosen from four
different covariance structures (unstructured (UN), Huynh-
Feldt (HF), compound symmetry (CS), and first order auto-
regressive (AR1)) based on the smallest values of the Akaike
Information Criteria (AIC) and Bayesian Information
Criteria (BIC) [13]. The analysis of effects was carried
out after the selection of a covariance structure. The p-
values were calculated using Satterthwaite’s approximation
in PRO MIXED. Values were determined to be significantly
different when p < 0.05. All statistical analyses were per-
formed in SAS version 9.2 (Cary, North Carolina, USA),
and the above models were used.
Results
Characteristics of the Patients
During the study period, we screened 56 patients; 34 of
these fulfilled the inclusion criteria. Ten patients with-
drew informed consent. A flow chart depicting the en-
rolled patients is shown in Figure 1. Twenty-four cases
were ultimately enrolled and diagnosed as having pneu-
monia, urinary infections, bed sore infections, cellulitis,
and intra-abdominal abscesses. Five cases (20.8%) died of
the sepsis episode separately on days 2, 5, 7, 10, and 10.
The characteristics of the enrolled cases are given in Table 1.
Assessed for eligibility (n = 56)
 Death (n = 5) Survival (n =19)
- Mid-term (n = 6)
- Long-term (n = 13) 
Excluded (n = 32)
- Cardiac origin (n = 10)
- Not meeting inclusion criteria 
  of sepsis (n = 11)
- Survival < 12 hours (n = 2)
- Declined to participate (n = 10)
- Withdrawal (n = 1) 
Figure 1 Flow chart of the cases included in this study.
Table 1 Characteristics of the severe sepsis patients





Median survival time (days) 6.46 45 NA
Female/male 1/4 1/5 9/4
Age (years) 72.0 ± 13.6 64.8 ± 13.5 78.0 ± 11.5
Pneumonia 2 4 5
K. pneumoniae 0 0 0
MSSA 0 0 1
MRSA 1 1 0
H. influenzae 0 1 0
E. cloacae, K. pneumoniae 1 0 0
S. marcescens 0 0 1
E. coli 0 1 0
Urinary tract infection 1 0 3
K. pneumoniae 1 0 0
E. coli 0 0 1
E. coli, A. baumannii 0 0 1
Bed sore infection 1 0 0
M. morganii 1 0 0
C. albicans 0 0 0
Cellulitis 0 0 1
Intra-abdominal abscess 1 2 4
E. coli 0 1 0
A. baumannii, S. maltophilia 0 1 0
A. lwoffii 0 0 1
K. pneumonia 1 0 0
Blood culture positive rate 100% 83.3% 38.5%
Death: cases who died due to sepsis; Mid-term survival: cases who survived sepsis
but died or were in continued hospitalization within six months; Long-term
survival: cases who had complete recovery and survived >6 months.
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a secondary infection on days 19, 44, 45, 49 and 176 due to
sepsis/septic shock, and one was hospitalized due to re-
peated infections in six months. The patient with continued
hospitalization for six months was diagnosed with necrotiz-
ing pancreatitis with persistent multiple intra-abdominal
abscesses. This patient was transferred to the ICU of an-
other hospital after a six-month hospitalization at NTUH.
The patients in the recovery group were healthy upon dis-
charge from the hospital in less than six months from
admittance.
The levels of CD3+, CD4+, CD8+, and CD19+ lymphocytes
in the early death and survival groups are not
significantly different
The dynamic changes in the proportions of CD3+, CD4+,
CD8+, CD19+ lymphocytes in the death and survival groups
are shown in sections A, C, E, and G of Figure 2. A de-
crease in the CD3+, CD4+ and CD8+ lymphocyte levels
was observed in the death group on day 3. Compared to
the CD8+ lymphocyte level, the proportion of the CD4+
lymphocytes was lower in the death group on day 3. An
overall comparison between these two groups revealed
no significant differences using a mixed model, as shown
in Table 2.
The levels of CD3+ and CD4+ lymphocytes in the mid-term
survival group are lower than those in the long-term
survival group
Comparisons of the lymphocyte subpopulations of the
MTSG and LTSG are shown in sections B, D, F, and H
of Figure 2. The levels of CD3+ and CD4+ lymphocytes
were lower in the MTSG than in the LTSG. Although
lymphocyte apoptosis has been reported in sepsis, the
observation that there are lower levels of CD3+ and CD4+
lymphocytes in the MTSG is novel. The results of themixed model are shown in Table 2. No significant differ-
ences were found between the lymphocyte subpopulations
of the MTSG and LTSG.
The levels of MCP-1, IL-6, and IL-8 in the early death and
survival groups were significantly different
Comparisons of the CA IX, MCP-1, IL-6, IL-7, IL-8, and
IL-10 levels in the death and survival groups are shown
in sections A, C, E, G, I, and K of Figure 3. A statistical
analysis of the overall difference between the groups is
shown in Table 3. The plasma levels of MCP-1, IL-6, and
IL-8 were significantly different in the death and survival
groups, with p-values all less than 0.01. The plasma levels
of IL-10 in the death group were higher than those of the
survival group after day 0. Imbalanced levels of inflamma-
tory and anti-inflammatory cytokines were present in the





















































































































Figure 2 Comparisons of lymphocyte subpopulations between the death and survival groups (2A, 2C, 2E, and 2G) and between the
mid-term and long-term survival groups (2B, 2D, 2F, and 2H). The mean ± standard error of each group at each time point are shown; the
subpopulation frequencies are LOG10 transformed. The differences between the groups were considered to be significant when p < 0.05. CA:
carbonic anhydrase.
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Table 2 Comparisons of the percentages of CD3+, CD4+, CD8+, and CD19+ lymphocytes in the death and survival
groups and the long-term survival group (LTSG) and mid-term survival group (MTSG) using a mixed model
Survival Group versus Death Group LTSG versus MTSG
Variable Model-Based Test p Variable Model-Based Test p
Estimated Mean*(SE) Estimated Mean*(SE)
CD3+ T 0.08 0.79 CD3+ T 0.55 0.47
Survival 1.72 (0.04) LTSG 1.74 (0.04)
Death 1.76 (0.06) MTSG 1.70 (0.05)
CD4+ T 0.24 0.63 CD4+ T 0.01 0.93
Survival 1.43 (0.05) LTSG 1.44 (0.06)
Death 1.48 (0.09) MTSG 1.45 (0.07)
CD8+ T 0.36 0.55 CD8+ T 0.05 0.83
Survival 1.34 (0.06) LTSG 1.34 (0.05)
Death 1.27 (0.09) MTSG 1.36 (0.07)
CD19+ B cell 3.63 0.07 CD19+ B cell 0.14 0.71
Survival 1.17 (0.12) LTSG 1.15 (0.07)
Death 0.67 (0.24) MTSG 1.18 (0.08)
CD3+ T cells: the percentage of CD3+ T cells in lymphocytes; CD19+ B cells: the percentage of CD19+ B cells in lymphocytes.
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long-term survival groups were significantly different
Comparisons of the plasma variables of the MTSG
and LTSG are shown in sections B, D, F, H, J, and L
of Figure 3. The overall levels of MCP-1 (p < 0.01), IL-6
(p = 0.04), and IL-8 (p < 0.01) in the mid-term and long-
term survival groups were significantly different based on
the mixed model.
Discussion
The plasma levels of MCP-1, IL-6, and IL-8 in the early
death and survival groups were significantly different dur-
ing the early stages of the sepsis episode. The surviving
patients recovered from this infection, while the others
died from a secondary infection. The plasma levels of IL-
6, IL-8, and MCP-1 in these two groups of patients were
significantly different; this is a novel finding of the study.
Our data support the hypothesis that sepsis survivors have
a weaker pro-inflammatory response than non-survivors
and reject the hypothesis that mid-term survivors have
a more pronounced anti-inflammatory response. The
duration of immunosuppression after SIRS is not known.
One MTSG case died on day 176, and one case was hospi-
talized for more than six months. Therefore, the recovery
group was designated as those patients who were healthy
at the time of discharge from the hospital and lived longer
than six months after sepsis.
A finely tuned balance between pro- and anti-inflamma
tory events is a prerequisite for better prognosis in sepsis.
T-helper (Th)1 response predominates after microbial in-
fection, which activates cells to directly clear an infection.
Th2 cytokine secretion is then induced to resolve the
pro-inflammatory response and to stimulate a humoralresponse. However, during sepsis, a Th2 response causes the
dysregulation of the cellular immune response instead of re-
solving infection. Th2 cytokines inhibit the Th1 response,
and vice versa. IL- 10, a potent anti-inflammatory cytokine,
has a strong suppressive effect on monocytes/macrophages,
dendritic cells, neutrophils and T cells [14]. In this study, the
plasma levels of IL-10 were not significantly different in the
early death group versus the survivors or in the MTSG ver-
sus the LTSG. Higher levels of IL-10 were present in the
MTSG on day 0, which implies that the MTSG was experi-
encing immunosuppression. Although the levels of IL-6, IL-
8, and MCP-1 in the MTSG and LTSG were signifi-
cantly different in the early phase, the MTSG patients
survived until the secondary infection. High levels of IL-
8 and MCP-1 would attract, activate, and promote neu-
trophil and monocyte migration toward the site of
inflammation, as well as to the remote organs. Excessive
neutrophil and monocyte infiltration exaggerates inflamma-
tion and severe organ injury by releasing pro-inflammatory
mediators, such as IL-6, which can lead to shock, multiple
organ failure, and even death [15].
Our results indicate that IL-6, IL-8, and MCP-1 were
much more potent than IL-10 in promoting death due
to a secondary infection. Factors other than IL-10 may
be more effective in inhibiting inflammation in the early
phase of sepsis. IL-7 has anti-apoptotic properties and
induces the proliferation of CD4+ and CD8+ naïve T cells
[15]. Because lymphocyte apoptosis has been reported in
sepsis, the level of IL-7 was expected to be higher in the
survival group and the LTSG. However, the levels of IL-
7 were higher in both the death group and the MTSG,
which conflicts with our expectations. A further investi-
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Figure 3 (See legend on next page.)
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Figure 3 Comparisons of CA IX, MCP-1, IL-6, IL-7, IL-8, and IL-10 between death and survival (3A, 3C, 3E, 3G, 3I, and 3K) and between
mid-term survival and long-term survival groups (3B, 3D, 3F, 3H, 3J and 3L). The mean ± standard error of each group at each time point
are presented in LOG10 transformation. The difference between groups was considered significant with p < 0.05. CA: carbonic anhydrase, MCP:
monocyte chemoattractant protein, IL: interleukin.
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cytes, particularly CD8+ lymphocytes in the death group
on day 3, was observed in this study. The level of CD19+
B lymphocytes in the death group was elevated on day 3;
this may be due to the decrease in the proportion of
both CD4+ and CD8+ lymphocytes. CD8+ lymphocytes
were most likely more fragile and eliminated more on
day 3. These effects also require further investigation.
No comparisons of the lymphocyte subpopulations of
patients who survive or died due to sepsis or between
MTSG and LTSG were conducted in previous studies. In
one example, the leukocyte subpopulations of 8 cases of
pneumonia-derived sepsis (PDS) with a 37.5% survival
rate and 14 cases of intra-abdominal sepsis (IAS) with a
35.7% survival rate were compared to those from normal
controls over the course of 4–6 days after the onset of
sepsis. Lymphocyte levels were diminished compared to
controls in both types of sepsis, and a marked drop in
CD3+CD8+ lymphocytes was observed [16]. Another
study reported that the levels of CD3+CD4+ and CD19+Table 3 Comparisons of the levels of CA IX, MCP-1, IL-6, IL-7,
long-term survival group (LTSG) and mid-term survival group
Survival Group versus Death Group
Variable Model-Based Test p
Estimated Mean* (SE)


















CA IX: carbonic anhydrase IX; MCP-1: monocyte chemoattractant protein-1.lymphocytes and the CD4+/CD8+ T cell ratio were sig-
nificantly lower in 25 septic shock non-survivors (P < 0.01)
compared to 27 survivors on the day of hospitalization;
however, there was no difference in the proportion of
CD3+CD8+ T lymphocytes between non-survivors and
survivors [17]. A discrimination of the MTSG and LTSG
was not conducted in their study. The zero time point
was also restricted in our study, whereas previous
authors defined day zero as the day of hospitalization;
one drawback of this approach is that the onset of sepsis
may not be clear. The number of cases included in this
study was reduced due to our strict definition of the
zero point to within 12 hours after the first organ failure
due to sepsis. More cases will be needed to validate
these results.
One of our inclusion criteria in the present study is
that patients were recruited with 12 hours after the first
organ failure due to sepsis as the zero time point. It
caused that we were not able to recruit enough patients.
Thus, the main limitation of the present study is theIL-8 and IL-10 in the death and survival groups and the
(MTSG) using a mixed model
LTSG versus MTSG
Variable Model-Based Test p
Estimated Mean* (SE)
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will be needed for validation.
The presence of high levels of MCP-1, IL-6, IL-8, and
IL-10 in the death group in our study indicated an im-
balance of inflammation and anti-inflammation; this im-
balance promotes overwhelming inflammation, leading to
death. The levels of MCP-1, IL-6, and IL-8 in the early
death and survival groups and between the MTSG and
LTSG were significantly different. Pro-inflammatory cyto-
kines were more prominent in the MTSG.
Conclusions
Our data support the hypothesis that sepsis survivors
would have a weaker pro-inflammatory response than
non-survivors, whereas mid-term survivors did not have
a more pronounced anti-inflammatory response. The levels
of pro-inflammatory cytokines were significantly different
in mid-term and long-term survivors.
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